Barbara Schaeffler

Barbara Schaeffler's Title

Barbara Schaeffler holds the esteemed title of Vice President, Clinical Development Operations at Zymeworks. In this pivotal role, she oversees the strategic planning and execution of clinical trials, ensuring that all phases—from initial design to regulatory submissions—are meticulously managed. Her leadership in this position is crucial for Zymeworks' mission to develop innovative therapeutics for the treatment of cancer and other serious diseases.

Barbara Schaeffler's Education and Expertise

Barbara Schaeffler is well-educated, holding an MBA along with a bachelor's degree in Bacteriology from the University of California. Her academic background provides a solid foundation in both the scientific and business aspects of the biopharma industry. This dual expertise enables her to bridge the gap between research and executive management, making her a versatile and strategic leader in clinical development operations.

Barbara Schaeffler's Experience

With over 27 years of experience in the biotechnology and biopharma industries, Barbara Schaeffler has an extensive background in clinical development and operations. She has held senior roles at reputable organizations such as Lundbeck, Alder Biopharmaceuticals, Poniard Pharmaceuticals, Pathogenesis, Chiron, and PATH. Her vast experience includes leading departments and project development teams through all phases of clinical trials, culminating in successful regulatory filings and drug approvals. This depth of experience makes her an invaluable asset to any organization she joins.

Barbara Schaeffler's Previous Roles

Before joining Zymeworks, Barbara Schaeffler served as Vice President of Clinical Operations at Syndax Pharmaceuticals. In this role, she was instrumental in advancing the company's clinical pipeline, overseeing trial design and execution. Her tenure at Syndax was marked by significant achievements in clinical development, contributing to the company's growth and success. Her previous roles at notable companies such as Lundbeck, Alder Biopharmaceuticals, Poniard Pharmaceuticals, Pathogenesis, Chiron, and PATH further highlight her seasoned expertise in the field.